-
US DOJ probes Eli Lilly’s Branchburg manufacturing site
pharmaceutical-technology
May 31, 2021
The US Department of Justice (DOJ) has issued a subpoena to Eli Lilly seeking some documents related to its manufacturing facility in Branchburg, New Jersey, US.
-
Purdue Pharma reaches agreement with DOJ over opioid medicines
pharmaceutical-technology
October 23, 2020
Purdue Pharma has reached an $8.3bn settlement agreement with the United States Department of Justice (DOJ) to resolve multi-year civil and criminal investigations into its past marketing practices related to its opioid medicines.
-
DOJ Announces Deal with Purdue Pharma, Civil Settlement with Sackler Family
americanpharmaceuticalreview
October 22, 2020
The Department of Justice (DOJ) has announced a global resolution of its criminal and civil investigations into the opioid manufacturer Purdue Pharma, and a civil resolution of its civil investigation into individual shareholders from the Sackler family.
-
US DoJ calls for increased Covid-19 monoclonal antibody production
pharmaceutical-technology
July 27, 2020
The US Department of Justice (DoJ) has said that it will not challenge efforts by drugmakers to share information to scale up the manufacturing of monoclonal antibody treatments for Covid-19.
-
DOJ indicts 2nd opioid distributor for role in illegally pushing pills despite warning signs
fiercepharma
July 20, 2019
With federal scrutiny mounting on claims it profiteered from the nation’s opioid epidemic, Ohio-based Miami-Luken shuttered its doors for good last year.
-
DOJ Asks Congress to Permanently Classify Fentanyl-Like Drugs
drugs
July 04, 2019
DOJ Asks Congress to Permanently Classify Fentanyl-Like Drugs.
-
AmerisourceBergen says civil penalty to resolve DOJ probe now at $625M
fiercepharma
November 23, 2017
It turns out that the quarter-crushing $575 million that drug wholesaler AmerisourceBergen set aside to settle civil litigation with the Justice Department was not enough. It is going to take another $50 million.